#VisualAbstract: Atrasentan Reduced Proteinuria in IgA Nephropathy
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: eGFR
AstraZeneca’s Tagrisso and chemotherapy pairing have been approved in Canada for treatment in locally advanced or metastatic non-small cell lung cancer.
Tagrisso is the first-line therapy for patients whose lung cancer tumors have EGFR exon 19 deletions or exon 21 substitution ...
Johnson and Johnson: The subcutaneous formulation of Rybrevant was more effective than the intravenous formulation in reducing the risk of death in lung cancer patients.
The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination ...
Gefitinib with Chemotherapy in EGFR-Mutated Lung Cancer
1. The median overall survival was 17.6 months in the gefitinib group vs 27.5 months in the gefitinib plus chemotherapy ...
eGFR is more strongly associated with adverse outcomes when cystatin C is included
1. In this cohort study, estimated glomerular filtration rate based on both creatinine and cystatin C (eGFRcr-cys ) was more strongly ...
#VisualAbstract: Amivantamab plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions Showed Superior Progression-Free Survival Than Chemotherapy Alone
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
#VisualAbstract: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Cystatin C-based equation without race or sex improves accuracy of GFR estimation
1. In this cross-sectional study, serum cystatin C levels were similar in both Black and White patients at the same ...
#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease
Click here to read this study in NEJM
SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes
1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and ...